NEW YORK, Sept. 20, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) and certain of its officers. The class action lawsuit, filed in the United States District Court for the Central District of California and registered number 22-cv-06764, is on behalf of a group of individuals and entities that acquired Fulgent’s publicly traded securities between March 22, 2019 and August 4, 2022, both dates inclusive (the “Collection Period”), in an attempt to recover damages caused by Defendants’ violations of the federal securities laws and remedies under Sections 10(b) and 20(a ) of the Securities Exchange Act of 1934 (the “Exchange Act”) and rule 10b-5 made thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Fulgent securities during the class action period, you have until November 21, 2022 to ask the court to appoint you as lead plaintiff in the class action. A copy of the complaint is available at www.pomerantzlaw.com. To discuss this promotion, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Persons inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Fulgent, along with its subsidiaries, provides COVID-19, molecular diagnostics and genetic testing services to physicians and patients in the United States and internationally. As a result, Fulgent must comply with the state anti-kickback statute, which prohibits knowingly and intentionally paying “fees” to induce or reward patient referrals or to transact business involving items or services that are payable by state healthcare programs. as well as the Federal Stark Act, which …